Investment in Thermo Fisher Scientific Inc. (TMO) over the past few years has accrued considerable profits, showing an earnings per share beating expectations which contributed to an upward trend in its stock price. TMO recently beat Q1 2024 EPS and revenue expectations, delivering a strong first quarter and lifting its outlook for the rest of the year. As it continues to show improved relative strength in the market, several investment firms including Boston Partners and Fiera Capital Corp have adjusted their stock positions in TMO. Despite potential economic headwinds, the firm maintains resilient performance due to its strong fundamentals. Meanwhile, the UK's Competition and Market Authority (CMA) has launched a probe into the company's merger deal with bio-tech firm Olink. Additionally, the biotech giant is also set to speak at the BofA Securities 2024 Health Care Conference on May 14. However, TMO's rising performance has given investors smaller returns as the broader market improves. Analysts remain positive about the company's future opportunities despite the stock showing periodic declines, due largely to its attractive financial prospects.
Thermo Fisher Scientific TMO News Analytics from Tue, 12 Sep 2023 07:00:00 GMT to Sun, 19 May 2024 11:35:24 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -5
